Regression of Melanoma Nodules in a Patient Treated With Ranitidine

Tom Smith; Jeffrey W. Clark; Martin B. Popp

doi:10.1001/archinte.1987.00370100129020

Regression of Melanoma Nodules in a Patient Treated With Ranitidine

Tom Smith, Jeffrey W. Clark, Martin B. Popp

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Human malignant melanoma may regress spontaneously or with immunotherapy, such as Calmette-Guerin bacillus, interferon alfa, interleukin-2, and interleukin-2 plus lymphokine-activated killer cells. Histamine type 2 receptor antagonists can modulate immune function by inhibiting suppressor T-cell induction and activity, and melanoma regressions have been reported after the use of cimetidine with coumarin or interferon alfa. This article describes the complete regression of melanoma nodules in a patient treated with ranitidine hydrochloride, another histamine type 2—receptor antagonist. Ranitidine and cimetidine should be considered to be possibly active immunotherapeutic agents in the design and evaluation of clinical trials.

Original language	English (US)
Pages (from-to)	1815
Number of pages	1
Journal	Archives of internal medicine
Volume	147
Issue number	10
DOIs	https://doi.org/10.1001/archinte.1987.00370100129020
State	Published - Oct 1987
Externally published	Yes

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.1001/archinte.1987.00370100129020

Cite this

@article{6d558e29d8374ae8a8d43d0219378fe1,

title = "Regression of Melanoma Nodules in a Patient Treated With Ranitidine",

abstract = "Human malignant melanoma may regress spontaneously or with immunotherapy, such as Calmette-Guerin bacillus, interferon alfa, interleukin-2, and interleukin-2 plus lymphokine-activated killer cells. Histamine type 2 receptor antagonists can modulate immune function by inhibiting suppressor T-cell induction and activity, and melanoma regressions have been reported after the use of cimetidine with coumarin or interferon alfa. This article describes the complete regression of melanoma nodules in a patient treated with ranitidine hydrochloride, another histamine type 2—receptor antagonist. Ranitidine and cimetidine should be considered to be possibly active immunotherapeutic agents in the design and evaluation of clinical trials.",

author = "Tom Smith and Clark, {Jeffrey W.} and Popp, {Martin B.}",

year = "1987",

month = oct,

doi = "10.1001/archinte.1987.00370100129020",

language = "English (US)",

volume = "147",

pages = "1815",

journal = "Archives of internal medicine (Chicago, Ill. : 1908)",

issn = "2168-6106",

publisher = "American Medical Association",

number = "10",

}

TY - JOUR

T1 - Regression of Melanoma Nodules in a Patient Treated With Ranitidine

AU - Smith, Tom

AU - Clark, Jeffrey W.

AU - Popp, Martin B.

PY - 1987/10

Y1 - 1987/10

N2 - Human malignant melanoma may regress spontaneously or with immunotherapy, such as Calmette-Guerin bacillus, interferon alfa, interleukin-2, and interleukin-2 plus lymphokine-activated killer cells. Histamine type 2 receptor antagonists can modulate immune function by inhibiting suppressor T-cell induction and activity, and melanoma regressions have been reported after the use of cimetidine with coumarin or interferon alfa. This article describes the complete regression of melanoma nodules in a patient treated with ranitidine hydrochloride, another histamine type 2—receptor antagonist. Ranitidine and cimetidine should be considered to be possibly active immunotherapeutic agents in the design and evaluation of clinical trials.

AB - Human malignant melanoma may regress spontaneously or with immunotherapy, such as Calmette-Guerin bacillus, interferon alfa, interleukin-2, and interleukin-2 plus lymphokine-activated killer cells. Histamine type 2 receptor antagonists can modulate immune function by inhibiting suppressor T-cell induction and activity, and melanoma regressions have been reported after the use of cimetidine with coumarin or interferon alfa. This article describes the complete regression of melanoma nodules in a patient treated with ranitidine hydrochloride, another histamine type 2—receptor antagonist. Ranitidine and cimetidine should be considered to be possibly active immunotherapeutic agents in the design and evaluation of clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=0023200833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023200833&partnerID=8YFLogxK

U2 - 10.1001/archinte.1987.00370100129020

DO - 10.1001/archinte.1987.00370100129020

M3 - Article

C2 - 3662709

AN - SCOPUS:0023200833

SN - 2168-6106

VL - 147

SP - 1815

JO - Archives of internal medicine (Chicago, Ill. : 1908)

JF - Archives of internal medicine (Chicago, Ill. : 1908)

IS - 10

ER -

Regression of Melanoma Nodules in a Patient Treated With Ranitidine

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this